MUFG Americas Holdings Corp lifted its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 480,911 shares of the company’s stock after purchasing an additional 4,319 shares during the quarter. Merck & accounts for 1.0% of MUFG Americas Holdings Corp’s investment portfolio, making the stock its 24th largest holding. MUFG Americas Holdings Corp’s holdings in Merck & were worth $30,821,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of MRK. IFP Advisors Inc raised its position in shares of Merck & by 1.8% during the first quarter. IFP Advisors Inc now owns 88,478 shares of the company’s stock worth $5,622,000 after purchasing an additional 1,572 shares during the period. First Midwest Bank Trust Division grew its stake in Merck & by 0.5% in the 1st quarter. First Midwest Bank Trust Division now owns 32,017 shares of the company’s stock valued at $2,035,000 after purchasing an additional 153 shares during the period. Leavell Investment Management Inc. grew its stake in Merck & by 2.0% in the 1st quarter. Leavell Investment Management Inc. now owns 74,490 shares of the company’s stock valued at $4,733,000 after purchasing an additional 1,459 shares during the period. Breton Hill Capital Ltd. grew its stake in Merck & by 84.3% in the 1st quarter. Breton Hill Capital Ltd. now owns 44,981 shares of the company’s stock valued at $2,858,000 after purchasing an additional 20,577 shares during the period. Finally, Palo Capital Inc. bought a new position in Merck & in the 1st quarter valued at $283,000. 73.15% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/13/mufg-americas-holdings-corp-raises-stake-in-merck-company-inc-mrk.html.
In other news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.25% of the company’s stock.
Shares of Merck & Company, Inc. (NYSE MRK) opened at $55.48 on Monday. The firm has a market capitalization of $151,151.77, a P/E ratio of 14.26, a PEG ratio of 2.39 and a beta of 0.78. Merck & Company, Inc. has a 1 year low of $54.41 and a 1 year high of $66.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.
Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period last year, the company earned $1.07 EPS. equities research analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current year.
A number of brokerages have issued reports on MRK. J P Morgan Chase & Co set a $70.00 price objective on Merck & and gave the company a “buy” rating in a research note on Sunday, October 29th. Berenberg Bank reaffirmed a “hold” rating on shares of Merck & in a research report on Wednesday, November 1st. BMO Capital Markets set a $70.00 price target on Merck & and gave the company a “buy” rating in a research report on Wednesday, October 18th. Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $74.00 price target (down previously from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Merck & has an average rating of “Hold” and an average price target of $67.07.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.